Table 2.
Induction remission trials in antineutrophil cytoplasmic antibody−associated vasculitis
| Trial | Compared | Results | Rates |
|---|---|---|---|
| CYCAZAREM | CYP vs. CYP/AZA | Equal remission | 93% |
| NORAM | MTX vs. CYP | Equal remission | 89% vs. 90% |
| CYCLOPS | i.v. vs. oral CYP | Equal remission | 88.1% vs. 87.7% |
| RAVE | RTX vs. CYP | Equal remission: better response in relapsers and PR3-with RTX | 64% vs. 53% (off steroids by 6 mo) 72% vs 42% in relapsers |
| RITUXIVAS | RTX/CYP vs. CYP/AZA |
Equal remission | 76 vs. 82% |
| MYCYC | MMF vs. CYP | Equal remission but may need more steroids | 73% vs. 74% 90% vs. 88% with more steroids |
AZA, azathioprine; CYCAZAREM, cyclophosphamide vs. azathioprine for early remission phase of vasculitis; CYP, cyclophosphamide; CYCLOPS, randomized trial of daily oral versus pulse cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate; MYCYC, clinical trial of mycophenolate versus cyclophosphamide; NORAM, nonrenal Wegener's granulomatosis treated alternatively with methotrexate; RAVE, rituximab for ANCA-associated vasculitis; RITUXVAS, open label trial comparing a rituximab-based regimen with a standard cyclophosphamide/azathioprine regimen; RTX, rituximab.